Dr. Beer has authored and co-authored more than 300 articles and abstracts on prostate cancer largely focusing on the development of novel therapies through clinical and translational investigation. He recently co-authored the book Cancer Clinical Trials: A Commonsense Guide to Experimental Cancer Therapies and Clinical Trials. Dr. Beer’s major research interests include clinical trials, preclinical investigation, and risk factors in prostate cancer. Dr. Beer was also selected as one of six top scientists to take part in a research Dream Team that joins together world-class institutions to study treatments for advanced prostate cancer.
Dr. Beer is a specialist in prostate cancer care. In a recent interview with ascopost.com, Dr. Beer noted that both abiraterone (Zytiga) and enzalutamide (Xtandi) have shown benefit in docetaxel-naive patients with metastatic disease, yet presently there are no head-to-head comparisons to guide treatment selection. He added “We have two active drugs for patients. My hope is that our future studies will further define which patients benefit from which approach. For now, we have encouraging results for both drugs and we will treat patients by making decisions one at a time.”
Don’t miss Dr. Tomasz Beer on Saturday, September 12, as well as many other esteemed prostate cancer experts covering a wide variety of topics, including: Chemotherapy, Xofigo, Bone Health, Immune Therapy, Seed Implant Radiation, Active Surveillance, and managing the sexual side effects of treatment.